CytoDyn Inc. (OTCMKTS:CYDY) Files An 8-K Regulation FD Disclosure
Item7.01. Regulation FD Disclosure.
On January5, 2017, CytoDyn Inc. posted to its corporate website a
letter to its shareholders. A copy of the letter is furnished
with this Form 8-K
and is attached as Exhibit 99.1 hereto.
Item9.01.
Financial Statements and Exhibits.
| (d) |
|
|
||
| 99.1 | Letter to Shareholders, dated January5, 2017. |
About CytoDyn Inc. (OTCMKTS:CYDY)
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company’s product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man. CytoDyn Inc. (OTCMKTS:CYDY) Recent Trading Information
CytoDyn Inc. (OTCMKTS:CYDY) closed its last trading session down -0.020 at 0.680 with 132,848 shares trading hands.
